Lunasin is a bioactive peptide originally isolated from soybean. One major impediment on the potential health benefits of lunasin is its susceptibility to be digested after oral ingestion. The objectives of this research is to prepare different lunasin-enriched products (LEP) and determine the effect of inherent protease inhibitors on the stability of lunasin against pepsin-pancreatin hydrolysis (PPH). LEP stability was compared to commercially-available LEP (cLEP). LEP were produced by calcium and pH precipitation methods and the capability of LEP to inhibit inflammasomes activation using THP-1 human macrophages was evaluated. The concentrations of lunasin, Kunitz trypsin inhibitor (KTI) and Bowman-Birk inhibitor (BBI) are higher in laboratory-produced LEP than cLEP. The concentrations of KTI and BBI correlated to percentage residual lunasin after PPH. The importance of KTI on lunasin stability against PPH was further confirmed by utilizing soybean flours with KTI mutations. Soybean flour with mutations in two KTI isoforms had lower residual lunasin after PPH than control soybean flour (8.6% vs 12.3%, P &lt; 0.05). At 400 µg/mL, pre-treatment of calcium precipitated LEP inhibited inflammasomes activation by reducing IL-1β secretion in THP-1 human macrophages by 70.3% and modifying the expression of NLRP3, caspase-1 and ASC proteins important in inflammasomes activation. This study is the first to report on the important role of KTI in protecting lunasin against PPH and the capability of LEP to modify the inflammasomes potentially supporting the health-benefits associated with consumption of lunasin-based products.<br/>

Lunasin-enriched products: Effect of Kunitz trypsin and Bowman-Birk protease inhibitors on stability against pepsin-pancreatin hydrolysis and modification of the inflammasomes <i>in vitro</i>

253rd National Meeting (2017)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.

Lunasin-enriched products: Effect of Kunitz trypsin and Bowman-Birk protease inhibitors on stability against pepsin-pancreatin hydrolysis and modification of the inflammasomes in vitro